For Q1 FY2026 ended March 31, 2026, Aktis Oncology reported revenue of $3.227 million, up 123% year-over-year, and a net loss of $18.325 million, widening 22.3% from the prior year. Operating loss was $22.706 million, up 25.2% year-over-year. Diluted EPS was -$0.38, compared to -$0.19 in the prior year. The company held $371.63 million in cash and $506.108 million in equity, with no long-term debt.
•Revenue grew 123% YoY to $3.227 million.
•Net loss widened 22.3% YoY to $18.325 million.
•Cash and cash equivalents stood at $371.63 million.
•No long-term debt on the balance sheet.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Aktis Oncology, Inc., a clinical-stage oncology company provides the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers.
The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors
Including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors including prostate, lung and solid tumors.
It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. Incorporated in 2020 and headquartered in Boston, Massachusetts, Aktis Oncology was formerly known as HotKnot Therapeutics, Inc. before rebranding in April 2020.
Aktis Oncology, Inc. is a clinical-stage biotechnology company focused on the research, development, and commercialization of targeted radiopharmaceuticals for treating various solid tumor cancers. Its lead product candidate is [225Ac]Ac-AKY-1189, a miniprotein radioconjugate currently in a Phase 1b clinical trial for Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another candidate, [225Ac]Ac-AKY-2519, targets B7-H3 (CD276) expressing tumors such as prostate, lung, and other solid tumors. The company also has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly.
Where is Aktis Oncology (AKTS) listed and what currency does it trade in?
Aktis Oncology is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol AKTS. Its shares are traded in US dollars (USD), reflecting its primary listing in the United States. The company is headquartered in Boston, Massachusetts, and operates within the US market, though its clinical trials and collaborations may have international components.
What sector and industry does Aktis Oncology (AKTS) belong to?
Aktis Oncology operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage oncology company, it focuses on developing targeted radiopharmaceuticals—a specialized area of biotech that combines radioactive isotopes with targeting molecules to treat cancer. This places it among companies that research and develop novel therapies for solid tumors, leveraging radioconjugate technology to deliver radiation directly to cancer cells.
Where is Aktis Oncology (AKTS) headquartered and what is its history?
Aktis Oncology is headquartered in Boston, Massachusetts, United States. The company was incorporated in 2020 and was originally known as HotKnot Therapeutics, Inc. before rebranding to Aktis Oncology in April 2020. Its focus on targeted radiopharmaceuticals for solid tumors has led to collaborations with organizations such as Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company's clinical-stage pipeline includes candidates targeting Nectin-4 and B7-H3 expressing tumors.
What is the business model of Aktis Oncology (AKTS) and how does it generate revenue?
Aktis Oncology is a clinical-stage biotechnology company that generates revenue primarily through research and development activities, as well as collaboration and license agreements. It has entered into agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly, which likely involve upfront payments, milestone payments, and royalties on future product sales. The company's lead candidates, [225Ac]Ac-AKY-1189 and [225Ac]Ac-AKY-2519, are in clinical trials and have not yet been commercialized. Therefore, Aktis Oncology currently does not generate revenue from product sales but relies on partnerships and funding to advance its pipeline.